Home Cart Sign in  
Chemical Structure| 700874-72-2 Chemical Structure| 700874-72-2

Structure of Galunisertib
CAS No.: 700874-72-2

Chemical Structure| 700874-72-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LY2157299 is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM in a cell-free assay.

Synonyms: LY2157299

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Galunisertib

CAS No. :700874-72-2
Formula : C22H19N5O
M.W : 369.42
SMILES Code : O=C(C1=CC=C2N=CC=C(C3=C(CCC4)N4N=C3C5=NC(C)=CC=C5)C2=C1)N
Synonyms :
LY2157299
MDL No. :MFCD12923319
InChI Key :IVRXNBXKWIJUQB-UHFFFAOYSA-N
Pubchem ID :10090485

Safety of Galunisertib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • TGFβRI/ALK5

    TβRI, IC50:56 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
human naïve CD4+ T cells 10 µg/ml 5 days Galunisertib potently suppressed the differentiation of PD-1+CXCR5+ cells induced by Activin A PMC4955732
HLE cells 10 µM 48 h Galunisertib significantly reduced the expression of CD44 and THY1 in HLE and HLF cells, indicating that Galunisertib modulates the stemness phenotype of HCC cells by inhibiting the TGF-β signaling pathway. PMC5841307
HLF cells 10 µM 48 h Galunisertib significantly reduced the expression of CD44 and THY1 in HLE and HLF cells, indicating that Galunisertib modulates the stemness phenotype of HCC cells by inhibiting the TGF-β signaling pathway. PMC5841307
HLF cells 10 μM 2 h and 48 h To study the effect of Galunisertib on TGF-β1-induced gene expression, results showed that Galunisertib inhibited TGF-β1-induced gene upregulation. PMC5386488
HepG2 cells 10 μM 2 h and 24 h To study the effect of Galunisertib on TGF-β1-induced gene expression in HepG2 cells, results showed that Galunisertib had different effects on gene expression at different time points. PMC5386488
HLE cells 10 μM 2 h and 24 h To study the effect of Galunisertib on TGF-β1-induced gene expression in HLE cells, results showed that Galunisertib had different effects on gene expression at different time points. PMC5386488
AGS cells 5 µM 8 h Inhibition of TGF-β1 signaling pathway, reversal of EMT activation PMC11568101
SGC-7901 cells 5 µM 8 h Inhibition of TGF-β1 signaling pathway, reversal of EMT activation PMC11568101
Panc1 10μM 48 h To evaluate the effect of chemotherapeutic agents on tumor cell immunogenicity, results showed that Gemcitabine significantly enhanced the expression of PD-L1, PD-L2, CTLA-4, HLA-A,B,C, and CD86 PMC7777391
hPSC 10μM 48 h To evaluate the effect of Galunisertib on immunomodulatory proteins in hPSC cells, results showed that Galunisertib significantly inhibited the induction of immunomodulatory proteins by Panc1-GR conditioned media PMC7777391
HepG2 cells 10 µM 48 h Galunisertib significantly inhibited the TGFβ1-induced phosphorylation of Smad2 and Smad3, indicating that the 3D liver scaffolds can be used as a drug screening platform. PMC7017194

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice subcutaneous tumor model intraperitoneal injection 300 µg/mouse every 5 days for 3 weeks Galunisertib treatment significantly reduced the volume and weight of subcutaneous tumors PMC11568101
Mice SMAD4-deficient colorectal cancer model Oral 75 mg/kg Once daily for 7 days Galunisertib inhibited the metastasis rate of SMAD4-deficient CRC cells and significantly reduced the proportion of intratumoral G-MDSCs. PMC11365421
Nude mice Subcutaneous xenograft model Oral 800 mg/kg Once daily for an appropriate duration Galunisertib treatment rescued the increased tumor growth and lung metastasis caused by HOOK1 knockdown, thereby prolonging the survival of tumor-bearing nude mice PMC10265082
Mice KC and KCT mouse models Intraperitoneal injection 75mg/kg Twice weekly for four months To evaluate the effect of combined Galunisertib and anti-PD-1 therapy on pancreatic cancer, results showed that in the setting of TGFβ signaling deficiency, the combination therapy significantly enhanced CD8+ T-cell response and reduced tumor burden PMC7777391

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03206177 Carcinosarcoma, Ovarian Phase 1 Recruiting June 1, 2022 United States, Oklahoma ... More >> University of Oklahoma Health Sciences Center Recruiting Oklahoma City, Oklahoma, United States, 73104 Contact: Kathleen Moore, MD Less <<
NCT01373164 Neoplasms Neo... More >>plasm Metastasis Pancreatic Cancer Less << Phase 1 Phase 2 Completed - United States, Florida ... More >> Florida Hospital Tampa HPG and Foregut Surgery Tampa, Florida, United States, 33613 United States, Illinois Ingalls Memorial Hospital Harvey, Illinois, United States, 60426 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 Belgium For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Brussel, Belgium, 1000 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Liège, Belgium, 4000 France For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Besancon, France, 25030 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Clermont-Ferrand, France, 63003 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Marseille, France, 13273 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Montbéliard, France, 25250 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Paris, France, 75674 Germany For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Frankfurt, Germany, 60596 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Friedrichshafen, Germany, 88045 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leipzig, Germany, 04103 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Marburg, Germany, 35043 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Munich, Germany, 81925 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Mönchengladbach, Germany, 41063 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Reutlingen, Germany, 72764 Italy For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bergamo, Italy, 24128 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bologna, Italy, 40138 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Verona, Italy, 37134 Spain For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Barcelona, Spain, 08035 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Madrid, Spain, 28033 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Pozuelo De Alarcon, Spain, 28223 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Sevilla, Spain, 41013 Less <<
NCT01373164 - Completed - -
NCT01682187 Glioma Phase 1 Active, not recruiting May 1, 2019 United States, Maryland ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Baltimore, Maryland, United States Spain For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Barcelona, Spain For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Madrid, Spain For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Sevilla, Spain Less <<
NCT01220271 Glioma Phase 1 Phase 2 Completed - United States, California ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. La Jolla, California, United States, 92093 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. San Francisco, California, United States, 94143 United States, Florida For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tampa, Florida, United States, 33612 United States, Illinois For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chicago, Illinois, United States, 60611 United States, Indiana For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Indianapolis, Indiana, United States, 46202 United States, North Carolina For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Durham, North Carolina, United States, 27710 Germany For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Frankfurt, Germany, 60596 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Heidelberg, Germany, 69120 Spain For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Barcelona, Spain, 08035 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Madrid, Spain, 28041 Less <<
NCT01246986 Carcinoma, Hepatocellular Phase 2 Active, not recruiting December 3, 2018 -
NCT01582269 Glioblastoma Phase 2 Active, not recruiting December 31, 2019 -
NCT02538471 Metastatic Breast Cancer Phase 2 Active, not recruiting August 2019 United States, New York ... More >> Weill Cornell Medical College New York, New York, United States, 10065 Less <<
NCT02178358 Hepatocellular Carcinoma Phase 2 Active, not recruiting December 31, 2018 China ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Beijing, China, 100036 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bengbu, China, 233004 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Changchun, China, 130012 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hangzhou, China, 310016 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hefei, China, 230022 Hong Kong For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hong Kong, Hong Kong For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Kowloon, Hong Kong Korea, Republic of For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Incheon, Korea, Republic of, 405-760 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Seoul, Korea, Republic of, 135 720 Taiwan For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Gwei Shan Township, Taiwan, 333 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Liouying/Tainan, Taiwan, 736 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Puzih City, Taiwan, 613 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tainan, Taiwan, 70403 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Taipei, Taiwan, 11217 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Taoyuan, Taiwan, 33378 Thailand For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bangkok, Thailand, 10330 Less <<
NCT02672475 Estrogen Receptor Negative ... More >> HER2/Neu Negative Progesterone Receptor Negative Recurrent Breast Carcinoma Stage IV Breast Cancer Triple-Negative Breast Carcinoma Less << Phase 1 Recruiting June 2021 United States, Tennessee ... More >> Vanderbilt University/Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: G. VICC Clinical Trials Information Program    800-811-8480       Principal Investigator: Vandana G. Abramson, MD Less <<
NCT02008318 Myelodysplastic Syndromes Phase 2 Phase 3 Completed - Germany ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Dresden, Germany, 01307 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Düsseldorf, Germany, 40479 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Jena, Germany, 07747 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Lübeck, Germany, 23562 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Ulm, Germany, 89081 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Westerstede, Germany, 26655 Italy For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Firenze, Italy, 50134 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Novara, Italy, 28100 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Rome, Italy, 00161 Spain For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Barcelona, Spain, 08035 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Madrid, Spain, 28050 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Oviedo, Spain, 33011 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Salamanca, Spain, 37007 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Valencia, Spain, 46026 Less <<
NCT03470350 Colorectal Cancer Metastatic PHASE1|PHASE2 WITHDRAWN 2020-06-01 Antoni van Leeuwenhoek (NKI-AV... More >>L), Amsterdam, Noord-Holland, 1066 CX, Netherlands Less <<
NCT02734160 Metastatic Pancreatic Cancer Phase 1 Active, not recruiting June 17, 2019 United States, Arizona ... More >> Honor Health Research Institute Scottsdale, Arizona, United States, 85258 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Tennessee Sarah Cannon Research Institute SCRI Nashville, Tennessee, United States, 37203 Tennessee Oncology PLLC Nashville, Tennessee, United States, 37203 France Gustave Roussy Villejuif Cedex, France, 94805 Italy Ospedale Policlinico Giambattista Rossi, Borgo Roma Verona, Italy, 37134 Korea, Republic of Samsung Medical Center Seoul, Korea, Korea, Republic of, 06351 Seoul National University Hospital Seoul, Korea, Republic of, 03080 Spain Hospital Universitari Vall d'Hebron Barcelona, Spain, 08035 Hospital Universitario 12 de Octubre Madrid, Spain, 28041 Hospital Madrid Norte Sanchinarro Madrid, Spain, 28050 Less <<
NCT02304419 Neoplasm PHASE1 COMPLETED 2025-08-16 Memorial Sloan Kettering Cance... More >>r Center, New York City, New York, 10065, United States Less <<
NCT02452008 Prostate Cancer Phase 2 Recruiting July 2021 United States, District of Col... More >>umbia Sibley Memorial Hospital Recruiting Washington, District of Columbia, United States, 20016 Contact: Janice Powers, RN    202-660-5772    jpower22@JHMI.EDU    Principal Investigator: Channing Paller, MD          United States, Illinois Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Maha Hussain, MD    312-908-5487    maha.hussain@northwestern.edu    Principal Investigator: Maha Hussain, MD          University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Russel Szmulewitz, MD    773-702-7609    rszmulew@medicine.bsd.uchicago.edu    Contact: Kelly O'Connor    773-702-4653    koconnor@medicine.bsd.uchicago.edu    Principal Investigator: Russel Szmulewitz, MD          United States, Maryland Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21205 Contact: Channing Paller, MD    410-614-6321    cpaller@JHMI.EDU    Contact: Irina Rifkind, RN    410-502-2043    irifkin1@JHMI.EDU    Principal Investigator: Channing Paller, MD Less <<
NCT02688712 Rectal Adenocarcinoma Phase 2 Recruiting June 2022 United States, Oregon ... More >> Providence Cancer Center Recruiting Portland, Oregon, United States, 97213 Contact: Larissa Lundgren    503-215-2614    Larisa.Lundgren@providence.org    Sub-Investigator: Walter J. Urba, M.D., Ph.D          Sub-Investigator: Rachel Sanborn, MD          Sub-Investigator: Todd Crocenzi, MD          Sub-Investigator: Bernard Fox, Ph.D          Sub-Investigator: Michael Gough, Ph.D.          Sub-Investigator: Stephen Bader, MD          Sub-Investigator: Alice Wang-Chesebro, MD          Sub-Investigator: Matthew Solhjem, MD          Sub-Investigator: Rui Li, MD, PhD          Sub-Investigator: Rom Leidner, MD          Sub-Investigator: Marka Crittenden, MD, PhD          Sub-Investigator: Steven Seung, MD, PhD          Sub-Investigator: Mark Whiteford, MD          Sub-Investigator: David Page, MD          Sub-Investigator: John Godwin, MD Less <<
NCT01746004 Healthy Volunteers Phase 1 Completed - United States, Wisconsin ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Madison, Wisconsin, United States, 53704 Less <<
NCT02752919 Healthy PHASE1 COMPLETED 2025-06-16 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds, West Yorkshire, United Kingdom Less <<
NCT01965808 Healthy Volunteers PHASE1 COMPLETED 2025-12-13 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, 31227, United States Less <<
NCT01722825 Neoplasms|Neoplasm Metastasis PHASE1 COMPLETED 2025-06-14 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559 ) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, 104-0045, Japan Less <<
NCT02154646 Pancreatic Neoplasms Phase 1 Completed - Japan ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chiba, Japan, 277 8577 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tokyo, Japan, 104-0045 Less <<
NCT02240433 Hepatocellular Carcinoma Phase 1 Active, not recruiting February 11, 2019 Japan ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chiba, Japan, 277 8577 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Kanagawa, Japan, 241-8515 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Suita-shi, Japan, 565-0871 Less <<
NCT02423343 Solid Tumor N... More >>on-Small Cell Lung Cancer Recurrent Hepatocellular Carcinoma Recurrent Less << Phase 1 Phase 2 Recruiting December 20, 2019 United States, Alabama ... More >> University of Alabama at Birmingham Medical Center Recruiting Birmingham, Alabama, United States, 35294 Contact    2059961403       Principal Investigator: Mansoor Noorali Saleh          United States, California University of California - San Diego Recruiting La Jolla, California, United States, 92093 Contact    858-534-3804       Principal Investigator: Sandip Patel          United States, Florida H Lee Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612-9497 Contact    813-745-2677       Principal Investigator: Scott J Antonia          United States, Massachusetts Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact    617-632-2166       Principal Investigator: David A Reardon          United States, Texas University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact    713-563-2169       Principal Investigator: David S Hong          Spain Hospital Universitari Vall d'Hebron Recruiting Barcelona, Spain, 08035 Contact    34932746085       Principal Investigator: Elena Garralda Cabanas          Institut Catala d'Oncologia Recruiting Barcelona, Spain, 08907 Contact    34932607744       Principal Investigator: Ernest Nadal Alforja          Hospital Universitario 12 de Octubre Recruiting Madrid, Spain, 28041 Contact    34913908626       Principal Investigator: Santiago Ponce Aix          Hospital Regional Universitario de Málaga Recruiting Malaga, Spain, 29010 Contact    34951030543       Principal Investigator: Manuel Cobo Dols Less <<
NCT02906397 ADVANCED HEPATOCELLULAR CARCIN... More >>OMA (HCC) Less << Phase 1 Active, not recruiting January 2019 United States, Pennsylvania ... More >> Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.71mL

0.54mL

0.27mL

13.53mL

2.71mL

1.35mL

27.07mL

5.41mL

2.71mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories